Review article: The investigation and management of gastric neuroendocrine tumours

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 10, 2014, Pages 1071-1084

  Basuroy, R ^a   Srirajaskanthan, R ^a,b   Prachalias, A ^a   Quaglia, A ^a   Ramage, J K ^a,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY HOSPITAL LEWISHAM   (United Kingdom)

^c BASINGSTOKE AND NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; NETAZEPIDE; PROTON PUMP INHIBITOR; SOMATOSTATIN DERIVATIVE;

ACHLORHYDRIA; ATROPHIC GASTRITIS; CANCER INCIDENCE; CANCER PROGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC SUBMUCOSAL DISSECTION; ENDOSCOPIC SURGERY; ENDOSCOPY; GASTRIC CARCINOID TYPE 1; GASTRIC CARCINOID TYPE 2; GASTRIC CARCINOID TYPE 3; GASTRIN BLOOD LEVEL; GASTRINOMA; HISTOLOGY; HUMAN; HYPERGASTRINEMIA; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL GASTRECTOMY; PRIORITY JOURNAL; REVIEW; SCINTIGRAPHY; STOMACH ANTRUM RESECTION; STOMACH CARCINOID; SYSTEMATIC REVIEW; TOTAL STOMACH RESECTION; TUMOR VOLUME;

DISSECTION; ENDOSCOPY; GASTRINS; GASTRITIS, ATROPHIC; HUMANS; NEUROENDOCRINE TUMORS; POLYPS; PROGNOSIS; STOMACH NEOPLASMS;

EID: 84899045606     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12698     Document Type: Review

References (114)

1. Modlin IM, Latich I, Zikusoka M, Kidd M, Eick G, Chan AK,. Gastrointestinal carcinoids: the evolution of diagnostic strategies. J Clin Gastroenterol 2006; 40: 572-82.
2. Modlin IM, Lye KD, Kidd M,. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol 2004; 99: 23-32.
3. Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM,. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011; 40: 1-18, vii.
4. Lawrence B, Kidd M, Svejda B, Modlin I,. A clinical perspective on gastric neuroendocrine neoplasia. Curr Gastroenterol Rep 2011; 13: 101-9.
5. Niederle MB, Hackl M, Kaserer K, Niederle B,. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer 2010; 17: 909-18.
6. Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E,. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 1993; 104: 994-1006.
7. Delle FG, Kwekkeboom DJ, Van CE, et al,. ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology 2012; 95: 74-87.
8. Ellis L, Shale MJ, Coleman MP,. Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971. Am J Gastroenterol 2010; 105: 2563-9.
9. Lehy T, Roucayrol AM, Mignon M,. Histomorphological characteristics of gastric mucosa in patients with Zollinger-Ellison syndrome or autoimmune gastric atrophy: role of gastrin and atrophying gastritis. Microsc Res Tech 2000; 48: 327-38.
10. Gencosmanoglu R, Sen-Oran E, Kurtkaya-Yapicier O, Avsar E, Sav A, Tozun N,. Gastric polypoid lesions: analysis of 150 endoscopic polypectomy specimens from 91 patients. World J Gastroenterol 2003; 9: 2236-9.
11. Scherubl H, Cadiot G, Jensen RT, Rosch T, Stolzel U, Kloppel G,. Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: small tumors, small problems? Endoscopy 2010; 42: 664-71.
12. Dockray GJ,. Clinical endocrinology and metabolism. Gastrin. Best Pract Res Clin Endocrinol Metab 2004; 18: 555-68.
13. Fanelli MF, Chinen LT, Begnami MD, et al,. The influence of transforming growth factor-alpha, cyclooxygenase-2, matrix metalloproteinase (MMP)-7, MMP-9 and CXCR4 proteins involved in epithelial-mesenchymal transition on overall survival of patients with gastric cancer. Histopathology 2012; 61: 153-61.
14. Sanui A, Yotsumoto F, Tsujioka H, et al,. HB-EGF inhibition in combination with various anticancer agents enhances its antitumor effects in gastric cancer. Anticancer Res 2010; 30: 3143-9.
15. Pritchard DM, Berry D, Przemeck SM, Campbell F, Edwards SW, Varro A,. Gastrin increases mcl-1 expression in type I gastric carcinoid tumors and a gastric epithelial cell line that expresses the CCK-2 receptor. Am J Physiol Gastrointest Liver Physiol 2008; 295: G798-805.
16. Bordi C,. Gastric carcinoids. Ital J Gastroenterol Hepatol 1999; 31 (Suppl. 2): S94-7.
17. Solcia E, Bordi C, Creutzfeldt W, et al,. Histopathological classification of nonantral gastric endocrine growths in man. Digestion 1988; 41: 185-200.
18. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al,. Hypergastrinaemia during long-term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infection. Aliment Pharmacol Ther 1998; 12: 605-12.
19. Vanoli A, La Rosa S, Luinetti O, et al,. Histologic changes in type A chronic atrophic gastritis indicating increased risk of neuroendocrine tumor development: the predictive role of dysplastic and severely hyperplastic enterochromaffin-like cell lesions. Hum Pathol 2013; 44: 1827-37.
20. Larsson H, Carlsson E, Hakanson R, et al,. Time-course of development and reversal of gastric endocrine cell hyperplasia after inhibition of acid secretion. Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology 1988; 95: 1477-86.
21. Klinkenberg-Knol EC, Nelis F, Dent J, et al,. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118: 661-9.
22. Kidd M, Miu K, Tang LH, et al,. Helicobacter pylori lipopolysaccharide stimulates histamine release and DNA synthesis in rat enterochromaffin-like cells. Gastroenterology 1997; 113: 1110-7.
23. Kloppel G, Anlauf M,. Gastrinoma-morphological aspects. Wien Klin Wochenschr 2007; 119: 579-84.
24. Anlauf M, Garbrecht N, Henopp T, et al,. Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features. World J Gastroenterol 2006; 12: 5440-6.
25. Jensen RT, Cadiot G, Brandi ML, et al,. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012; 95: 98-119.
26. Berna MJ, Annibale B, Marignani M, et al,. A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors. J Clin Endocrinol Metab 2008; 93: 1582-91.
27. Delle FG, Marignani M, Moretti A, D'Ambra G, Martino G, Annibale B,. Hypergastrinemia and enterochromaffin-like cell hyperplasia. Yale J Biol Med 1998; 71: 291-301.
28. Delle FG, Marignani M, Corleto VD, et al,. Progression of gastric enterochromaffin-like cells growth in Zollinger-Ellison syndrome and atrophic body gastritis patients. Dig Liver Dis 2002; 34: 270-8.
29. Nikou GC, Toubanakis C, Nikolaou P, et al,. Gastrinomas associated with MEN-1 syndrome: new insights for the diagnosis and management in a series of 11 patients. Hepatogastroenterology 2005; 52: 1668-76.
30. Zikusoka MN, Kidd M, Eick G, Latich I, Modlin IM,. The molecular genetics of gastroenteropancreatic neuroendocrine tumors. Cancer 2005; 104: 2292-309.
31. Borch K, Ahren B, Ahlman H, Falkmer S, Granerus G, Grimelius L,. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 2005; 242: 64-73.
32. Rindi G, Azzoni C, La Rosa S, et al,. ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 1999; 116: 532-42.
33. Annibale B, Azzoni C, Corleto VD, et al,. Atrophic body gastritis patients with enterochromaffin-like cell dysplasia are at increased risk for the development of type I gastric carcinoid. Eur J Gastroenterol Hepatol 2001; 13: 1449-56.
34. Rappel S, Altendorf-Hofmann A, Stolte M,. Prognosis of gastric carcinoid tumours. Digestion 1995; 56: 455-62.
35. Bordi C,. Gastric carcinoids: an immunohistochemical and clinicopathologic study of 104 patients. Cancer 1995; 75: 129-30.
36. Bordi C, Yu JY, Baggi MT, et al,. Gastric carcinoids and their precursor lesions. A histologic and immunohistochemical study of 23 cases. Cancer 1991; 67: 663-72.
37. Bosman FT, Carneiro F, Hruban RH, Theise ND,. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon: IARC, 2010.
38. Manfe AZ, Norberto L, Marchesini M, Lumachi F,. Usefulness of chromogranin A, neuron-specific enolase and 5-hydroxyindolacetic acid measurements in patients with malignant carcinoids. In Vivo 2011; 25: 1027-9.
39. Nikou GC, Lygidakis NJ, Toubanakis C, et al,. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues. Hepatogastroenterology 2005; 52: 731-41.
40. Zatelli MC, Torta M, Leon A, et al,. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. Endocr Relat Cancer 2007; 14: 473-82.
41. Gibril F, Reynolds JC, Lubensky IA, et al,. Ability of somatostatin receptor scintigraphy to identify patients with gastric carcinoids: a prospective study. J Nucl Med 2000; 41: 1646-56.
42. Vannella L, Sbrozzi-Vanni A, Lahner E, et al,. Development of type I gastric carcinoid in patients with chronic atrophic gastritis. Aliment Pharmacol Ther 2011; 33: 1361-9.
43. Marignani M, Delle FG, Mecarocci S, et al,. High prevalence of atrophic body gastritis in patients with unexplained microcytic and macrocytic anemia: a prospective screening study. Am J Gastroenterol 1999; 94: 766-72.
44. Thomas D, Tsolakis AV, Grozinsky-Glasberg S, et al,. Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study. Eur J Endocrinol 2013; 168: 185-93.
45. Merola E, Sbrozzi-Vanni A, Panzuto F, et al,. Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate. Neuroendocrinology 2012; 95: 207-13.
46. Nakamura S, Iida M, Yao T, Fujishima M,. Endoscopic features of gastric carcinoids. Gastrointest Endosc 1991; 37: 535-8.
47. Kitago M, Inada T, Igarashi S, Mizutani S, Ogata Y, Kubota T,. Multiple gastric carcinoid tumors with type A gastritis concomitant with gastric cancer: a case report. Oncol Rep 2001; 8: 343-6.
48. Reinecke P, Borchard F,. Pattern of gastric endocrine cells in microcarcinoidosis-an immunohistochemical study of 14 gastric biopsies. Virchows Arch 1996; 428: 237-41.
49. Singh R, Yao K, Anagnostopoulos G, Kaye P, Ragunath K,. Microcarcinoid tumor diagnosed with high-resolution magnification endoscopy and narrow band imaging. Endoscopy 2008; 40 (Suppl. 2): E12.
50. Campana D, Nori F, Piscitelli L, et al,. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol 2007; 25: 1967-73.
51. La Rosa S, Inzani F, Vanoli A, et al,. Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms. Hum Pathol 2011; 42: 1373-84.
52. Hosokawa O, Kaizaki Y, Hattori M, et al,. Long-term follow up of patients with multiple gastric carcinoids associated with type A gastritis. Gastric Cancer 2005; 8: 42-6.
53. Caruso ML, Pilato FP, D'Adda T, et al,. Composite carcinoid- adenocarcinoma of the stomach associated with multiple gastric carcinoids and nonantral gastric atrophy. Cancer 1989; 64: 1534-9.
54. Pasquinelli G, Santini D, Preda P, Cariani G, Bonora G, Martinelli GN,. Composite gastric carcinoma and precursor lesions with amphicrine features in chronic atrophic gastritis. Ultrastruct Pathol 1993; 17: 9-24.
55. Vannella L, Lahner E, Annibale B,. Risk for gastric neoplasias in patients with chronic atrophic gastritis: a critical reappraisal. World J Gastroenterol 2012; 18: 1279-85.
56. Mendelsohn G, de la Monte S, Dunn JL, Yardley JH,. Gastric carcinoid tumors, endocrine cell hyperplasia, and associated intestinal metaplasia. Histologic, histochemical, and immunohistochemical findings. Cancer 1987; 60: 1022-31.
57. Gladdy RA, Strong VE, Coit D, et al,. Defining surgical indications for type I gastric carcinoid tumor. Ann Surg Oncol 2009; 16: 3154-60.
58. Kim BS, Oh ST, Yook JH, Kim KC, Kim MG, Jeong JW,. Typical carcinoids and neuroendocrine carcinomas of the stomach: differing clinical courses and prognoses. Am J Surg 2010; 200: 328-33.
59. Varas MJ, Gornals JB, Pons C, et al,. Usefulness of endoscopic ultrasonography (EUS) for selecting carcinoid tumors as candidates to endoscopic resection. Rev Esp Enferm Dig 2010; 102: 577-82.
60. Grozinsky-Glasberg S, Thomas D, Strosberg JR, et al,. Metastatic type 1 gastric carcinoid: a real threat or just a myth? World J Gastroenterol 2013; 19: 8687-95.
61. Suzuki S, Ishii N, Uemura M, et al,. Endoscopic submucosal dissection (ESD) for gastrointestinal carcinoid tumors. Surg Endosc 2012; 26: 759-63.
62. Oshima T, Okugawa T, Hori K, et al,. Successful endoscopic submucosal dissection of gastric carcinoid in a patient with autoimmune gastritis and systemic lupus erythematosus. Intern Med 2012; 51: 1211-3.
63. Hulagu S, Senturk O, Aygun C, et al,. Endoscopic submucosal dissection for premalignant lesions and noninvasive early gastrointestinal cancers. World J Gastroenterol 2011; 17: 1701-9.
64. Li QL, Zhang YQ, Chen WF, et al,. Endoscopic submucosal dissection for foregut neuroendocrine tumors: an initial study. World J Gastroenterol 2012; 18: 5799-806.
65. Saito Y, Otake Y, Sakamoto T, et al,. Indications for and technical aspects of colorectal endoscopic submucosal dissection. Gut Liver 2013; 7: 263-9.
66. Onozato Y, Kakizaki S, Ishihara H, et al,. Endoscopic submucosal dissection for rectal tumors. Endoscopy 2007; 39: 423-7.
67. Saito Y, Sakamoto T, Fukunaga S, Nakajima T, Kiriyama S, Matsuda T,. Endoscopic submucosal dissection (ESD) for colorectal tumors. Dig Endosc 2009; 21 (Suppl 1): S7-12.
68. Saito Y, Uraoka T, Yamaguchi Y, et al,. A prospective, multicenter study of 1111 colorectal endoscopic submucosal dissections (with video). Gastrointest Endosc 2010; 72: 1217-25.
69. Zhou PH, Yao LQ, Qin XY, et al,. Advantages of endoscopic submucosal dissection with needle-knife over endoscopic mucosal resection for small rectal carcinoid tumors: a retrospective study. Surg Endosc 2010; 24: 2607-12.
70. Ozao-Choy J, Buch K, Strauchen JA, Warner RR, Divino CM,. Laparoscopic antrectomy for the treatment of type I gastric carcinoid tumors. J Surg Res 2010; 162: 22-5.
71. Grozinsky-Glasberg S, Kaltsas G, Gur C, et al,. Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours. Eur J Endocrinol 2008; 159: 475-82.
72. Campana D, Nori F, Pezzilli R, et al,. Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. Endocr Relat Cancer 2008; 15: 337-42.
73. Boyce M, Warrington S, Black J,. Netazepide, a gastrin/CCK(2) receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects. Br J Clin Pharmacol 2013; 689-98.
74. Boyce M, David O, Darwin K, Mitchell T, Johnston A, Warrington S,. Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects. Aliment Pharmacol Ther 2012; 36: 181-9.
75. Fossmark R, Sordal O, Jianu CS, et al,. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. Aliment Pharmacol Ther 2012; 36: 1067-75.
76. Moore AR, Boyce M, Steele IA, Campbell F, Varro A, Pritchard DM,. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis. PLoS ONE 2013; 8: e76462.
77. Lehy T, Cadiot G, Mignon M, Ruszniewski P, Bonfils S,. Influence of multiple endocrine neoplasia type 1 on gastric endocrine cells in patients with the Zollinger-Ellison syndrome. Gut 1992; 33: 1275-9.
78. Cadiot G, Laurent-Puig P, Thuille B, Lehy T, Mignon M, Olschwang S,. Is the multiple endocrine neoplasia type 1 gene a suppressor for fundic argyrophil tumors in the Zollinger-Ellison syndrome? Gastroenterology 1993; 105: 579-82.
79. Gibril F, Schumann M, Pace A, Jensen RT,. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore) 2004; 83: 43-83.
80. Norton JA, Melcher ML, Gibril F, Jensen RT,. Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment. Surgery 2004; 136: 1267-74.
81. Cadiot G, Vissuzaine C, Potet F, Mignon M,. Fundic argyrophil carcinoid tumor in a patient with sporadic-type Zollinger-Ellison syndrome. Dig Dis Sci 1995; 40: 1275-8.
82. Norton JA,. Gastrinoma: advances in localization and treatment. Surg Oncol Clin N Am 1998; 7: 845-61.
83. Naswa N, Sharma P, Soundararajan R, et al,. Diagnostic performance of somatostatin receptor PET/CT using 68 Ga-DOTANOC in gastrinoma patients with negative or equivocal CT findings. Abdom Imaging 2013; 38: 552-60.
84. Hassan MM, Phan A, Li D, Dagohoy CG, Leary C, Yao JC,. Risk factors associated with neuroendocrine tumors: a US-based case-control study. Int J Cancer 2008; 123: 867-73.
85. Rindi G, Bordi C, Rappel S, La Rosa S, Stolte M, Solcia E,. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg 1996; 20: 168-72.
86. Modlin IM, Lye KD, Kidd M,. Carcinoid tumors of the stomach. Surg Oncol 2003; 12: 153-72.
87. Giordano JA,. Gastric carcinoid syndrome diagnosed by endoscopy. Am J Gastroenterol 1981; 76: 41-3.
88. Gough DB, Thompson GB, Crotty TB, et al,. Diverse clinical and pathologic features of gastric carcinoid and the relevance of hypergastrinemia. World J Surg 1994; 18: 473-9.
89. Adhikari D, Conte C, Eskreis D, Urmacher C, Ellen K,. Combined adenocarcinoma and carcinoid tumor in atrophic gastritis. Ann Clin Lab Sci 2002; 32: 422-7.
90. Basuroy R, Srirajaskanthan R, Ramage JK,. A multimodal approach to the management of neuroendocrine tumour liver metastases. Int J Hepatol 2012; 2012: 819193.
91. Pavel M, Baudin E, Couvelard A, et al,. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012; 95: 157-76.
92. Modlin IM, Pavel M, Kidd M, Gustafsson BI,. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010; 31: 169-88.
93. Arnold R, Rinke A, Klose KJ, et al,. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 2005; 3: 761-71.
94. Faiss S, Pape UF, Bohmig M, et al,. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroentero-pancreatic tumors-the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003; 21: 2689-96.
95. Rinke A, Muller HH, Schade-Brittinger C, et al,. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656-63.
96. Appetecchia M, Baldelli R,. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. J Exp Clin Cancer Res 2010; 29: 19.
97. Okita NT, Kato K, Takahari D, et al,. Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma. Gastric Cancer 2011; 14: 161-5.
98. Kwekkeboom DJ, Krenning EP, Lebtahi R, et al,. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology 2009; 90: 220-6.
99. Kwekkeboom DJ, de Herder WW, van Eijck CH, et al,. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2010; 40: 78-88.
100. Banfield A, Green S, Ramage JK,. Neuroendocrine tumour management: a team approach. Hospital medicine 2005; 66: 37-42.
101. Strosberg J, Gardner N, Kvols L,. Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology 2009; 89: 471-6.
102. Tang LH, Gonen M, Hedvat C, Modlin IM, Klimstra DS,. Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods. Am J Surg Pathol 2012; 36: 1761-70.
103. Khan MS, Luong TV, Watkins J, Toumpanakis C, Caplin ME, Meyer T,. A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms. Br J Cancer 2013; 108: 1838-45.
104. Boninsegna L, Panzuto F, Partelli S, et al,. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. Eur J Cancer 2012; 48: 1608-15.
105. Kwon YH, Jeon SW, Kim GH, et al,. Long-term follow up of endoscopic resection for type 3 gastric NET. World J Gastroenterol 2013; 19: 8703-8.
106. Kuipers EJ,. Proton pump inhibitors and gastric neoplasia. Gut 2006; 55: 1217-21.
107. Brunner G, Athmann C, Schneider A,. Long-term, open-label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. Aliment Pharmacol Ther 2012; 36: 37-47.
108. Jianu CS, Lange OJ, Viset T, et al,. Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor. Scand J Gastroenterol 2012; 47: 64-7.
109. Jianu CS, Fossmark R, Viset T, et al,. Gastric carcinoids after long-term use of a proton pump inhibitor. Aliment Pharmacol Ther 2012; 36: 644-9.
110. McCarthy DM,. Adverse effects of proton pump inhibitor drugs: clues and conclusions. Curr Opin Gastroenterol 2010; 26: 624-31.
111. McCarthy DM,. Commentary: a gastrin antagonist against carcinoids-implications for PPI-induced hypergastrinaemia. Aliment Pharmacol Ther 2013; 37: 276-7.
112. Dakin GF, Warner RR, Pomp A, Salky B, Inabnet WB,. Presentation, treatment, and outcome of type 1 gastric carcinoid tumors. J Surg Oncol 2006; 93: 368-72.
113. Lewis MA, Yao JC,. Molecular pathology and genetics of gastrointestinal neuroendocrine tumours. Curr Opin Endocrinol Diabetes Obes 2014; 21: 22-7.
114. van EM, Sundin A, Krenning EP, Kwekkeboom DJ,. Neuroendocrine tumours: the role of imaging for diagnosis and therapy. Nat Rev Endocrinol 2014; 10: 102-14.